Validation of chemiluminescent enzyme immunoassay in detection of autoantibodies in pemphigus and pemphigoid

Yumi Fujio, Kazuo Kojima, Masahiro Hashiguchi, Masatoshi Wakui, Mitsuru Murata, Masayuki Amagai, Jun Yamagami

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background A novel chemiluminescent enzyme immunoassay (CLEIA) was recently developed to quantify autoantibodies specific for desmogleins (Dsgs) and BP180, the target antigens of pemphigus and pemphigoid. This assay is automated and highly accurate and efficient. Objective To validate the use of the CLEIA for detection of autoantibodies during the clinical courses of patients with pemphigus and pemphigoid. Methods To define cut-off values for Dsg1, Dsg3, and BP180, we evaluated 47 serum samples from patients with pemphigus foliaceus (PF), 59 from those with pemphigus vulgaris (PV), 52 from those with bullous pemphigoid (BP), and 995 from healthy individuals. We also evaluated any fluctuations in CLEIA titers according to disease activity during the clinical course of 10 cases each of PF, PV, and BP. We used clinical symptom scores, the pemphigus disease area index (PDAI) and the bullous pemphigoid disease area index (BPDAI), to evaluate disease activity. Results The cut-off values for the CLEIA titers determined by the Youden index were 15.4 U/mL for Dsg1, 14.9 U/mL for Dsg3, and 16.8 U/mL for BP180. CLEIA titers fluctuated in parallel with the PDAI/BPDAI scores in 28 of the 30 cases with PF, PV, or BP. Although the CLEIA and enzyme-linked immunosorbent assay (ELISA) values in the same samples differed substantially in some cases, the concordance rates of positive/negative results between the CLEIA and ELISA were 96% for Dsg1, 97% for Dsg3, and 96% for BP180. Conclusion The CLEIA, a newly developed, highly effective autoantibody detection system, is as reliable as ELISA for evaluation of the clinical courses of pemphigus and pemphigoid.

Original languageEnglish
Pages (from-to)208-215
Number of pages8
JournalJournal of Dermatological Science
Volume85
Issue number3
DOIs
Publication statusPublished - 2017 Mar 1

Fingerprint

Bullous Pemphigoid
Pemphigus
Immunoenzyme Techniques
Autoantibodies
Enzymes
Immunosorbents
Assays
Enzyme-Linked Immunosorbent Assay
Desmogleins

Keywords

  • Autoantibody
  • Chemiluminescent enzyme immunoassay
  • Disease activity
  • Enzyme-linked immunosorbent assay
  • Pemphigoid
  • Pemphigus

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Dermatology

Cite this

Validation of chemiluminescent enzyme immunoassay in detection of autoantibodies in pemphigus and pemphigoid. / Fujio, Yumi; Kojima, Kazuo; Hashiguchi, Masahiro; Wakui, Masatoshi; Murata, Mitsuru; Amagai, Masayuki; Yamagami, Jun.

In: Journal of Dermatological Science, Vol. 85, No. 3, 01.03.2017, p. 208-215.

Research output: Contribution to journalArticle

@article{7724d7b02f25436abed29db9a1992684,
title = "Validation of chemiluminescent enzyme immunoassay in detection of autoantibodies in pemphigus and pemphigoid",
abstract = "Background A novel chemiluminescent enzyme immunoassay (CLEIA) was recently developed to quantify autoantibodies specific for desmogleins (Dsgs) and BP180, the target antigens of pemphigus and pemphigoid. This assay is automated and highly accurate and efficient. Objective To validate the use of the CLEIA for detection of autoantibodies during the clinical courses of patients with pemphigus and pemphigoid. Methods To define cut-off values for Dsg1, Dsg3, and BP180, we evaluated 47 serum samples from patients with pemphigus foliaceus (PF), 59 from those with pemphigus vulgaris (PV), 52 from those with bullous pemphigoid (BP), and 995 from healthy individuals. We also evaluated any fluctuations in CLEIA titers according to disease activity during the clinical course of 10 cases each of PF, PV, and BP. We used clinical symptom scores, the pemphigus disease area index (PDAI) and the bullous pemphigoid disease area index (BPDAI), to evaluate disease activity. Results The cut-off values for the CLEIA titers determined by the Youden index were 15.4 U/mL for Dsg1, 14.9 U/mL for Dsg3, and 16.8 U/mL for BP180. CLEIA titers fluctuated in parallel with the PDAI/BPDAI scores in 28 of the 30 cases with PF, PV, or BP. Although the CLEIA and enzyme-linked immunosorbent assay (ELISA) values in the same samples differed substantially in some cases, the concordance rates of positive/negative results between the CLEIA and ELISA were 96{\%} for Dsg1, 97{\%} for Dsg3, and 96{\%} for BP180. Conclusion The CLEIA, a newly developed, highly effective autoantibody detection system, is as reliable as ELISA for evaluation of the clinical courses of pemphigus and pemphigoid.",
keywords = "Autoantibody, Chemiluminescent enzyme immunoassay, Disease activity, Enzyme-linked immunosorbent assay, Pemphigoid, Pemphigus",
author = "Yumi Fujio and Kazuo Kojima and Masahiro Hashiguchi and Masatoshi Wakui and Mitsuru Murata and Masayuki Amagai and Jun Yamagami",
year = "2017",
month = "3",
day = "1",
doi = "10.1016/j.jdermsci.2016.12.007",
language = "English",
volume = "85",
pages = "208--215",
journal = "Journal of Dermatological Science",
issn = "0923-1811",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Validation of chemiluminescent enzyme immunoassay in detection of autoantibodies in pemphigus and pemphigoid

AU - Fujio, Yumi

AU - Kojima, Kazuo

AU - Hashiguchi, Masahiro

AU - Wakui, Masatoshi

AU - Murata, Mitsuru

AU - Amagai, Masayuki

AU - Yamagami, Jun

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Background A novel chemiluminescent enzyme immunoassay (CLEIA) was recently developed to quantify autoantibodies specific for desmogleins (Dsgs) and BP180, the target antigens of pemphigus and pemphigoid. This assay is automated and highly accurate and efficient. Objective To validate the use of the CLEIA for detection of autoantibodies during the clinical courses of patients with pemphigus and pemphigoid. Methods To define cut-off values for Dsg1, Dsg3, and BP180, we evaluated 47 serum samples from patients with pemphigus foliaceus (PF), 59 from those with pemphigus vulgaris (PV), 52 from those with bullous pemphigoid (BP), and 995 from healthy individuals. We also evaluated any fluctuations in CLEIA titers according to disease activity during the clinical course of 10 cases each of PF, PV, and BP. We used clinical symptom scores, the pemphigus disease area index (PDAI) and the bullous pemphigoid disease area index (BPDAI), to evaluate disease activity. Results The cut-off values for the CLEIA titers determined by the Youden index were 15.4 U/mL for Dsg1, 14.9 U/mL for Dsg3, and 16.8 U/mL for BP180. CLEIA titers fluctuated in parallel with the PDAI/BPDAI scores in 28 of the 30 cases with PF, PV, or BP. Although the CLEIA and enzyme-linked immunosorbent assay (ELISA) values in the same samples differed substantially in some cases, the concordance rates of positive/negative results between the CLEIA and ELISA were 96% for Dsg1, 97% for Dsg3, and 96% for BP180. Conclusion The CLEIA, a newly developed, highly effective autoantibody detection system, is as reliable as ELISA for evaluation of the clinical courses of pemphigus and pemphigoid.

AB - Background A novel chemiluminescent enzyme immunoassay (CLEIA) was recently developed to quantify autoantibodies specific for desmogleins (Dsgs) and BP180, the target antigens of pemphigus and pemphigoid. This assay is automated and highly accurate and efficient. Objective To validate the use of the CLEIA for detection of autoantibodies during the clinical courses of patients with pemphigus and pemphigoid. Methods To define cut-off values for Dsg1, Dsg3, and BP180, we evaluated 47 serum samples from patients with pemphigus foliaceus (PF), 59 from those with pemphigus vulgaris (PV), 52 from those with bullous pemphigoid (BP), and 995 from healthy individuals. We also evaluated any fluctuations in CLEIA titers according to disease activity during the clinical course of 10 cases each of PF, PV, and BP. We used clinical symptom scores, the pemphigus disease area index (PDAI) and the bullous pemphigoid disease area index (BPDAI), to evaluate disease activity. Results The cut-off values for the CLEIA titers determined by the Youden index were 15.4 U/mL for Dsg1, 14.9 U/mL for Dsg3, and 16.8 U/mL for BP180. CLEIA titers fluctuated in parallel with the PDAI/BPDAI scores in 28 of the 30 cases with PF, PV, or BP. Although the CLEIA and enzyme-linked immunosorbent assay (ELISA) values in the same samples differed substantially in some cases, the concordance rates of positive/negative results between the CLEIA and ELISA were 96% for Dsg1, 97% for Dsg3, and 96% for BP180. Conclusion The CLEIA, a newly developed, highly effective autoantibody detection system, is as reliable as ELISA for evaluation of the clinical courses of pemphigus and pemphigoid.

KW - Autoantibody

KW - Chemiluminescent enzyme immunoassay

KW - Disease activity

KW - Enzyme-linked immunosorbent assay

KW - Pemphigoid

KW - Pemphigus

UR - http://www.scopus.com/inward/record.url?scp=85008226634&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85008226634&partnerID=8YFLogxK

U2 - 10.1016/j.jdermsci.2016.12.007

DO - 10.1016/j.jdermsci.2016.12.007

M3 - Article

C2 - 28012821

AN - SCOPUS:85008226634

VL - 85

SP - 208

EP - 215

JO - Journal of Dermatological Science

JF - Journal of Dermatological Science

SN - 0923-1811

IS - 3

ER -